Analysis of proteins to differentiate between infected and non-infected ACLF patients
Not Applicable
- Conditions
- Health Condition 1: K74- Fibrosis and cirrhosis of liver
- Registration Number
- CTRI/2021/12/038725
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ACLF patients:
i. Age 18-80 years
ii. Giving a positive consent
Exclusion Criteria
Patients with
i. Human immunodeficiency virus infection
ii. Pregnancy,
iii. Previous liver or other organ transplantation
iv. Known immunosuppressed states (steroid use in previous 6 months) and
v. Those refusing to give consent will be excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the clinical and plasma proteomic profile between ACLF patients with culture-proven infections (bacterial and/or fungal) and ACLF patients without infectionsTimepoint: Recruitment & follow up of patients and simultaneous proteomic analysis for first 16 months. <br/ ><br>Validation of results in next 3 months. <br/ ><br>Final data analysis 3 months.
- Secondary Outcome Measures
Name Time Method